SCHEMBL3608184

SCHEMBL3608184

CN(CCNC(=O)Cn1ccc2cccc(-c3ccc(Cl)cc3)c21)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
MAPT P10636 3/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KDM4E B2RXH2 2/20 0.37
TP53 P04637 1/20 0.37
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPY5R Q15761 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
POLB P06746 1/20 0.36
CNR1 P21554 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594706 0.92 GAA (0.42) KMT2AGAATSHRMAPTNPSR1
SCHEMBL3597285 0.92 MAPT (0.46) KMT2AGAATSHRMAPTNPSR1
SCHEMBL3608258 0.91 GAA (0.43) KMT2AGAATSHRMAPTNPSR1
SCHEMBL3589634 0.91 GAA (0.38) KMT2AGAATSHRMAPTNPSR1
SCHEMBL3605919 0.90 MAPT (0.40) KMT2AGAATSHRMAPTNPSR1
SCHEMBL3605624 0.90 GAA (0.41) KMT2AGAATSHRMAPTNPSR1
SCHEMBL3589650 0.89 TSHR (0.41) KMT2AGAATSHRMAPTNPSR1
SCHEMBL3596537 0.87 GAA (0.41) KMT2AGAATSHRMAPTNPSR1
SCHEMBL3592315 0.86 GAA (0.42) KMT2AGAATSHRMAPTNPSR1
SCHEMBL3606203 0.86 CYP2D6 (0.45) KMT2AGAATSHRMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 KMT2A 3838/4885GAA 1982/4885TSHR 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.